Results 111 to 120 of about 192,514 (206)

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

Nature Communications
mRNA lipid nanoparticle (LNP) vaccines would be useful during an influenza virus pandemic since they can be produced rapidly and do not require the generation of egg-adapted vaccine seed stocks. Highly pathogenic avian influenza viruses from H5 clade 2.3.
Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad-Gabriel Alameh, Steven H. Y. Fan, Anthony T. Phan, Christopher A. Hunter, Richard J. Webby, Drew Weissman, Scott E. Hensley   +16 more
doaj   +1 more source

Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice

Viruses
Rotaviruses (RVs) are a major cause of diarrhea in young children worldwide. The currently available and licensed vaccines contain live attenuated RVs. Optimization of live attenuated RV vaccines or developing non-replicating RV (e.g., mRNA) vaccines is ...
Chenxing Lu, Yan Li, Rong Chen, Xiaoqing Hu, Qingmei Leng, Xiaopeng Song, Xiaochen Lin, Jun Ye, Jinlan Wang, Jinmei Li, Lida Yao, Xianqiong Tang, Xiangjun Kuang, Guangming Zhang, Maosheng Sun, Yan Zhou, Hongjun Li   +16 more
doaj   +1 more source

Development of mRNA rabies vaccines

Human Vaccines & Immunotherapeutics
Rabies, primarily transmitted to humans by dogs (accounting for 99% of cases). Once rabies occurs, its mortality rate is approximately 100%. Post-exposure prophylaxis (PEP) is critical for preventing the onset of rabies after exposure to rabid animals, and vaccination is a pivotal element of PEP.
Zixin Fang, Pengcheng Yu, Wuyang Zhu
openaire   +3 more sources

mRNA therapeutics: beyond vaccine applications [PDF]

Trends in Molecular Medicine, 2021
Bhat, Balkrishen, Karve, Shrirang, Anderson, Daniel G   +2 more
openaire   +2 more sources

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

npj Vaccines
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability.
Elena Mata, Esther Broset, Carlos Matute, Andrei Stoian, Susana Adame, Teresa Alejo, Alexandre López, Beatriz Andrés, Juan Heredero, Diego de Miguel, Javier Giménez-Warren, Verónica Lampaya, Diego Casabona, Alba Calvo, Gema Quincoces, Iván Peñuelas, Carlos Gamazo, Iratxe Uranga, Natacha Peña, Maykel Arias, Julián Pardo, Bernardino Moreno, Juan Badiola, Juan Martínez-Oliván, Esther Pérez-Herrán   +24 more
doaj   +1 more source

mRNA Therapeutics and mRNA Vaccines

TRENDS IN THE SCIENCES, 2021
openaire   +2 more sources

Age-related differences in mRNA vaccine immunogenicity and adjuvancy. [PDF]

Immunol Cell Biol
Chinni SS, Trollope GS, Leung P, McQualter JL, Tan CW, Wang L, Lim L, Wheatley AK, Juno JA, Kent SJ, Al-Wassiti HA, Pouton CW, Quinn KM.   +12 more
europepmc   +1 more source

AI-powered mapping of tumor immunity for optimized mRNA vaccine engineering. [PDF]

Front Oncol
Srivastava R.
europepmc   +1 more source

Multi-Epitope mRNA Vaccine Targeting <i>Dabie Bandavirus</i> Glycoprotein: An Immunoinformatics-Based Study. [PDF]

Bioinform Biol Insights
Ahmed SF, Paran MS, Munna MMR, Ahmed E, Majumder U, Rahmatullah M, Ali MZ.   +6 more
europepmc   +1 more source

Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection. [PDF]

ACS Nano
Cui L, Zhang S, Zeng Y, Zhang L, Lin M, Hong M, Chen H, Wang H, Xue W, Lan M, Liu H, Gao Y, Li H, Yin Y, Zhang H, Zheng Z, Chen Y, Chen J, Zhang Y, Gu Y, Li T, Li S, Xia N.   +22 more
europepmc   +1 more source